Biorchestra is an RNA therapeutics company based in Daejeon, South Korea, and Cambridge, Massachusetts. It develops RNA-based therapeutics using a BMD platform that can control microRNAs which regulate multiple messenger RNAs involved in disease. The company has developed a proprietary drug delivery system (BDDS™) for commercial drug development and reports IV-delivered ASO knock-down efficacy in cortex, hippocampus, striatum and spinal cord. Leadership includes CEO Branden (Jinhyeob) Ryu, CMO and US President Dr. Louis O’Dea, and CFO Young-Gil Kim. Biorchestra plans to use new funding to expand R&D and its product pipeline, complete a GMP facility, and initiate nonclinical toxicology programs. The company raised $45M in Series C financing to support these activities.

Total raised

$45M

Funding rounds

1

Latest round

Series C

Latest activity

Feb 2022